Overview

Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy

Status:
Active, not recruiting

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This phase I trial studies the side effects and best dose of ropidoxuridine in treating patients with gastrointestinal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment undergoing radiation therapy. Ropidoxuridine may help radiation therapy work better by making tumor cells more sensitive to the radiation therapy.

Phase:

Phase 1

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Ropidoxuridine